申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0352960A2
公开(公告)日:1990-01-31
Compounds of the formula (1):
and pharmaceutically acceptable salts thereof, wherein
R¹ is C???alkyl, C???alkenyl, C???cycloalkylC???alkyl, phenylC???alkyl or C???alkyl substituted by 1 to 6 fluoro groups;
R² is hydrogen, hydroxy, C???alkyl, phenyl, mercapto, C???alkylthio, CF? or amino;
R³ is hydrogen, nitro, amino, C???alkanoylamino, C???alkoxy, C???alkyl, halo, SO?NR?R?, CONR?R?, cyano or C???alkylS(O)n;
R? and R? are independently hydrogen or C???alkyl; and
n is 0, 1 or 2;
provided that R³ is not hydrogen when R¹ is C???alkyl or C???alkenyl and R² is hydrogen or hydroxy. Processes for their preparation, pharmaceutical compositions comprising them and their use as medicaments are described.
式(1)的化合物:
及其药学上可接受的盐,其中
R¹ 是 C???烷基、C???烯基、C???环烷基 C???烷基、苯基 C???烷基或被 1 至 6 个氟基团取代的 C??烷基;
R² 是氢、羟基、C??烷基、苯基、巯基、C??烷硫基、CF?或氨基;
R³ 是氢、硝基、氨基、C???烷酰氨基、C???烷氧基、C??烷基、卤素、SO?NR?R?、CONR?R?、氰基或 C??烷基S(O)n;
R? 和 R? 独立地为氢或 C??烷基;以及
n 是 0、1 或 2;
当 R¹ 为 C???烷基或 C???烯基,且 R² 为氢或羟基时,R³ 不是氢。本文介绍了它们的制备方法、包含它们的药物组合物以及它们作为药物的用途。